Healthcare
Lumos Diagnostics Holdings Limited(LDXHF)
Live Price
Offline$0.0817
+0.00% today
1Y Change
+308.50%
Window
Jun 25, 2025 → Jun 18, 2026
- Market Cap
- $90.00M
- Revenue Growth
- +12.3%
- EPS Growth
- +39.1%
- Dividend Yield
- 0.0%
Coverage: 249 bars · Jun 25, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Lumos Diagnostics Holdings Limited (LDXHF) is a Healthcare stock with a market cap of $90.00M and listed on OTC. The stock last traded around $0.08 and up 308.5% across the available one-year price window (Jun 25, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +12.3%, EPS growth of +39.1%, a dividend yield of 0.0%. What stands out right now is revenue +12.3%, EPS +39.1%, free cash flow -1207.0% with operating margin -81.5% and ROIC -85.8%. Valuation sits in the middle of the pack at price/sales 7.6. Stock Foundry combines LDXHF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+12.3% vs +7.6% peer median
Operating Margin
Below sector median
-81.5% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating story is still moving forward
Revenue is running at +12.3% and EPS at +39.1%, with operating margin around -81.5%.
Benchmark Edge
LDXHF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
LDXHF
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
LDXHF Max Drawdown
-74.50%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for LDXHF and SPY.
Company Overview
Lumos Diagnostics Holdings Limited
Other OTC
Lumos Diagnostics Holdings Limited, a contract research and development company, develops and commercializes rapid point-of-care (POC) diagnostic tests which are primarily focuses on the diagnosis and management of infectious diseases in the United States and Australia. The company products include FebriDx, a POC diagnostic test for detecting and differentiating viral and bacterial respiratory infections; ViraDx, a three-in-one POC test for influenza A, influenza B, and COVID-19.; and CoviDx, a rapid antigen test for COVID-19. It also offers desktop readers, disposable readers, and Lumos Leelu readers. Lumos Diagnostics Holdings Limited was founded in 2004 and is based in Melbourne, Australia.
- Leadership
- Douglas Ward
- IPO Date
- Sep 22, 2021
- Street Address
- Level 4
- Mailing
- Melbourne, VIC, 3205
- Region
- Melbourne, VIC, AU
- Reporting Currency
- USD
- Investor Line
- 61 3 9087 1598
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- —
- Price/Sales
- 7.6
- Price/Book
- 18.1
Growth
- Revenue
- +12.3%
- EPS
- +39.1%
- Free Cash Flow
- -1207.0%
Profitability
- Gross Margin
- 3.0%
- Operating Margin
- -81.5%
- Net Margin
- -75.8%
- ROE
- -164.1%
- ROIC
- -85.8%
Balance Sheet
- Debt/Equity
- 2.26
- Current Ratio
- 0.73
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.